GO:0015872 obsolete dopamine transport | Genes & Methods

GO:0015872, obsolete dopamine transport, is a retired Gene Ontology biological_process term that formerly described the directed movement of dopamine into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. Dopamine is a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline, and its transport is fundamental to synaptic transmission, motor control, and reward processing. Although the term is obsolete, the biology it captured remains a major research focus, particularly in Parkinson's disease and other dopamine-related disorders. The obsoletion reflects the Gene Ontology's ongoing refinement: dopamine transport is now decomposed into more precise terms covering dopamine uptake, vesicular packaging, and release, each with distinct molecular players and regulatory logic. For researchers, understanding the obsolete term is useful because legacy annotations, datasets, and publications still reference GO:0015872, and mapping these to current terms is essential for accurate meta-analysis and knowledge integration. This article reviews the definition, mechanism, key genes, disease relevance, and experimental methods associated with obsolete dopamine transport, with a focus on how CRISPR-based models can be used to interrogate the underlying biology.

In plain terms, GO:0015872 described how dopamine, a key brain chemical, gets moved around cells and across cell membranes. The QuickGO definition states: OBSOLETE. The directed movement of dopamine into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Dopamine is a catecholamine neurotransmitter and a metabolic precursor of noradrenaline and adrenaline. Because the term is obsolete, it should not be used for new annotations; instead, researchers should use current child terms that specify the direction, compartment, and molecular mechanism of dopamine movement.

Dopamine transport is a cornerstone of neurobiology because it controls the duration and amplitude of dopamine signaling at synapses, thereby influencing motor function, motivation, reward, and cognition. The obsolete term GO:0015872 served as a broad annotation for any directed dopamine movement, and although it has been retired, the underlying biology remains intensely studied, especially in Parkinson's disease where dopaminergic neuron loss and altered dopamine handling are central. Understanding the molecular machinery of dopamine transport, including DAT and VMAT2, is critical for developing therapeutic strategies such as benztropine-based DAT blockers. Moreover, accurate mapping of legacy annotations to current GO terms is essential for computational analyses and for interpreting high-throughput datasets.

The following genes and proteins are central to dopamine transport biology, including synthesis, vesicular packaging, reuptake, and regulation, as documented in the literature.

Dopamine transport is regulated at multiple levels. Transcriptional control of SLC6A3 and SLC18A2 determines transporter abundance, while post-translational modifications such as phosphorylation and ubiquitination control DAT surface expression and internalization. Kinase signaling, including PKC and ERK pathways, can rapidly alter DAT trafficking and activity. Additionally, substrate availability and ion gradients influence transport rate, and disease-associated proteins such as alpha-synuclein and LRRK2 can modulate dopamine transport dynamics. These regulatory layers ensure tight control of dopamine homeostasis and are often disrupted in Parkinson's disease and other disorders.

Parkinson's disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra and consequent dopamine deficiency in the striatum. Altered dopamine transport, including changes in DAT and VMAT2 function, contributes to disease pathophysiology and is a target for symptomatic therapy. Benztropine-based DAT blockers are being developed as potential interventions to modulate dopamine transport in Parkinson's disease. Mutations in genes such as SNCA, LRRK2, PINK1, PRKN, and PARK7 further link dopamine transport and neuronal survival.

The dopamine transporter is a key target of psychostimulants such as cocaine and amphetamines, which alter dopamine reuptake and increase synaptic dopamine. Dysregulation of dopamine transport is implicated in addiction and reward-related behaviors. Studying DAT function using knockout and knock-in models helps elucidate mechanisms of substance use disorders.

Dopamine transport dysfunction has been associated with attention-deficit/hyperactivity disorder (ADHD) and schizophrenia, where altered dopamine signaling contributes to symptoms. Genetic variants in SLC6A3 and related genes have been investigated in these conditions. Cell and animal models with modified dopamine transport genes are valuable for testing hypotheses about disease mechanisms.

Radiolabeled or fluorescent dopamine uptake assays in cell lines expressing DAT or VMAT2 are used to measure transport kinetics and inhibitor potency. These assays are essential for characterizing the functional impact of genetic variants and for screening benztropine-based compounds.

Fast-scan cyclic voltammetry and microdialysis can measure real-time dopamine release and reuptake in brain slices or in vivo. These techniques provide spatial and temporal resolution of dopamine dynamics and are often combined with genetic models.

Genome-wide CRISPR knockout or activation screens can identify modifiers of dopamine transport and toxicity. Such screens, coupled with bioinformatics, can reveal novel regulators of DAT trafficking and dopamine neuron survival.

RNA-seq and mass spectrometry-based proteomics can quantify expression changes in dopamine transport genes and interacting proteins under disease-relevant conditions. These approaches help map the molecular network around dopamine transport.

Researchers studying obsolete dopamine transport-related genes often need to determine whether a candidate gene is causally involved in dopamine handling, neuronal survival, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies of dopamine transport biology.

GO:0015872 obsolete dopamine transport is a retired Gene Ontology term that nonetheless captures a fundamental biological process: the directed movement of dopamine across cellular membranes and compartments. Although replaced by more specific terms, the underlying biology remains central to understanding neurotransmission, motor control, and reward, with profound implications for Parkinson's disease and other disorders. Advances in CRISPR-based models and transporter assays continue to illuminate the molecular players, including DAT and VMAT2, and to drive therapeutic development such as benztropine-based DAT blockers. Researchers should map legacy annotations to current GO terms and leverage modern genetic tools to dissect dopamine transport mechanisms.